The FDA has approved a first-of-its-kind oral medication for advanced metastatic pancreatic cancer. Experts regard the daily pill, daraxonrasib (Rasonque), as a groundbreaking new therapy for patients facing an exceptionally challenging illness.
“This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, MD, director of the FDA’s Oncology Center of Excellent, in a statement.
People with pancreatic cancer typically receive a diagnosis in later stages of the disease, making it one of the most difficult cancers to treat. The overall five-year survival rate is just 14 percent, and that number drops even lower if…
Read the full article at EVERYDAYHEALTH.COM